Skip to Content

Perforomist Approval History

FDA Approved: Yes (First approved May 11, 2007)
Brand name: Perforomist
Generic name: formoterol fumarate
Dosage form: Inhalation Solution
Company: Dey, L.P.
Treatment for: COPD

Perforomist is an inhalation solution formulation of the long-acting beta(2)-adrenergic agonist formoterol fumarate, indicated for the long-term, twice-daily maintenance treatment of bronchoconstriction for emphysema and chronic bronchitis, also known as Chronic Obstructive Pulmonary Disease (COPD).

Development History and FDA Approval Process for Perforomist

DateArticle
May 11, 2007Approval FDA Approves Dey, L.P.'s Perforomist (Formoterol Fumarate) Inhalation Solution for Maintenance Treatment of COPD

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide